Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects

Inclusion Criteria: * Willing to provide audio-visual \& written informed consent for participation in the study, and an ability to comprehend the nature and purpose of the study. * Willing to be available for the entire study period and to comply with protocol requirements. Should have reliable access to the clinical trial center and be available in the area for at least one month. * Normal, healthy, adult, human subject of 18-45 years (both inclusive) of age. * Body mass index in the range of 18 -30 kg/m2 (both inclusive). * Healthy volunteers who are clinically non-anemic will be included as per the discretion of PI/CI/Physician. * Non-diabetic healthy adult with HbA1c \< 5.5 at the time of study entry * Normal health status as determined by baseline medical and medication history, at the time of screening and vital signs (blood pressure, pulse rate, respiratory rate, and axillary temperature) measurements and physical examination at the time screening as well as check-in during each study period. * With normal or clinically non-significant laboratory values as determined by hematological, biochemistry tests and urine analysis (included in section no. 9.1). * With a normal or clinically non-significant 12-lead ECG. * With a negative test for Human Immunodeficiency Virus (HIV) type I/II antibodies or Hepatitis B surface antigen (HBsAg) or Hepatitis C virus antibodies. * Non-smokers and should not have been consuming any kind of tobacco products including chewing or inhalin…